Wednesday, March 18, 2026 10:49:30 AM
ALDX..................................................https://stockcharts.com/sc3/ui/?s=ALDX&p=w&b=5&g=0&id=p86431144783
Recent ALDX News
- Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX • PR Newswire (US) • 04/06/2026 08:58:00 AM
- Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX • PR Newswire (US) • 04/03/2026 05:07:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:25:05 PM
- Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDX • Business Wire • 04/01/2026 11:30:00 AM
- Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX • PR Newswire (US) • 04/01/2026 06:47:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:17:57 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 07:26:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 09:29:03 PM
- Aldeyra receives FDA rejection for dry eye treatment reproxalap • IH Market News • 03/17/2026 02:14:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:39:04 PM
- Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease • Business Wire • 03/17/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2026 10:07:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 09:47:10 PM
- Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference • Business Wire • 02/18/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 10:07:04 PM
- Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease • Business Wire • 12/16/2025 12:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 12:00:39 PM
- Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast • Business Wire • 11/13/2025 12:00:00 PM
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London • Business Wire • 11/11/2025 12:01:00 PM
- Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET • Business Wire • 11/06/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:16:42 PM
- Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules • Business Wire • 10/28/2025 11:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:00:28 AM
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference • Business Wire • 09/03/2025 11:01:00 AM
- Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma • Business Wire • 08/28/2025 11:01:00 AM
